Pfizer (NYSE:PFE) Price Target Raised to $30.00

Posted by George Bondi on Nov 7th, 2026

Pfizer (NYSE:PFE – Free Report) had its target price increased by UBS Group from $27.00 to $30.00 in a report published on Wednesday morning,Benzinga reports. UBS Group currently has a neutral rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on PFE. JPMorgan Chase & Co. upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Citigroup boosted their price objective on shares of Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Wednesday. BMO Capital Markets lowered their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Finally, Bank of America dropped their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Six research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $30.39.

Check Out Our Latest Analysis on Pfizer

Pfizer Stock Down 1.7%

NYSE:PFE traded down $0.50 during mid-day trading on Wednesday, reaching $29.38. The company’s stock had a trading volume of 48,291,518 shares, compared to its average volume of 30,697,644. Pfizer has a 1 year low of $23.62 and a 1 year high of $31.44. The stock has a fifty day moving average of $28.74 and a 200-day moving average of $26.90. The firm has a market capitalization of $167.46 billion, a PE ratio of 41.97, a price-to-earnings-growth ratio of 2.08 and a beta of 0.31. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.13. The company had revenue of $16.58 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the prior year, the business earned $0.87 EPS. Equities research analysts forecast that Pfizer will post 3.03 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is presently 245.71%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PFE. BlackRock Inc. lifted its position in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares during the last quarter. State Street Corp boosted its stake in Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after acquiring an additional 5,501,032 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Pfizer by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock valued at $1,393,739,000 after acquiring an additional 3,999,646 shares in the last quarter. Bank of America Corp DE purchased a new position in Pfizer in the second quarter worth $1,049,602,000. Finally, Dimensional Fund Advisors LP grew its holdings in Pfizer by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock worth $1,022,606,000 after purchasing an additional 293,029 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips